Francisco Adrián

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

<i>In silico</i> activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen

David Plouffe, Achim Brinker, Case W. McNamara et al. · Proceedings of the National Academy of Sciences · 2008 · 448 citations · Full text

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Francisco Adrián, Qiang Ding, Taebo Sim et al. · Nature Chemical Biology · 2006 · 376 citations · Full text

Molecular Pharmacology, Medicine, Allosteric Inhibitors +5

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

Michael Lampa, Heike Arlt, Timothy He et al. · PLoS ONE · 2017 · 156 citations · Full text

Breast Oncology, Tumor Cells, Metabolic Remodeling +18

A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors

Okram Barun, A. S. Nagle, Francisco Adrián et al. · Chemistry & Biology · 2006 · 145 citations · Full text

Molecular Pharmacology, General Strategy, Medicine +6